Showing results (571-580 of 673) with videos related to

Sort By:
Pageof 68
Journal of the American Heart Association|December 14, 2020
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare SystemJaejin An, Rong Wei, Hui Zhou, et al.
British Journal of Haematology|July 14, 2024
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practiceAnna L Godfrey, Nikolaos Sousos, Rebecca Frewin, et al.
European Heart Journal Open|August 3, 2022
Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failureHarshith R Avula, Andrew P Ambrosy, Michael J Silverberg, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
The Lancet. Haematology|September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trialClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Nature Genetics|January 17, 2024
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasmsJing Guo, Klaudia Walter, Pedro M Quiros, et al.
Leukemia & Lymphoma|June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trialVikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Leukemia|December 5, 2022
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patientsHosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
The New England Journal of Medicine|February 3, 2007
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisLinda M Scott, Wei Tong, Ross L Levine, et al.
Pageof 68